Retrospective evaluation of doxorubicin-piroxicam combination for the treatment of transitional cell carcinoma in dogs

C. Robat, Jenna H Burton, D. Thamm, D. Vail

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objectives: To determine whether doxorubicin-piroxicam combination is safe and has activity against transitional cell carcinoma in dogs. Methods: Data was collected retrospectively from 34 dogs from two institutions over a 6-year period. Signalment, clinical presentation, treatment specifics, adverse events, response, progression-free survival and overall survival time were evaluated. Results: Dogs received doxorubicin every 3 weeks and daily piroxicam; 17 dogs (50%) had surgery. Clinical presentations were those typically reported for transitional cell carcinoma. Mean number of doses administered was 3·5. Of the 23 dogs with measurable disease, 14 (60·5%) had stable disease, 7 (30·5%) had progressive disease and 2 (9%) a partial response. Adverse events were generally manageable, and gastrointestinal in origin; one dog died of treatment-related complications. Overall median progression-free survival and overall survival were 103 and 168 days, respectively. Cytoreductive surgery did not result in prolongation of progression-free survival, but significantly prolonged overall survival. All dogs but one died as a result of disease progression. Clinical Significance: Doxorubicin-piroxicam combination therapy is well-tolerated in dogs with transitional cell carcinoma although progression-free survival, overall survival and biological response rates appear modest. Combination with surgery appears to offer a survival advantage; however, this may reflect tumour location and volume. Prospective studies are necessary to compare activity of combination doxorubicin-piroxicam to currently applied therapies.

Original languageEnglish (US)
Pages (from-to)67-74
Number of pages8
JournalJournal of Small Animal Practice
Volume54
Issue number2
DOIs
StatePublished - Feb 2013
Externally publishedYes

Fingerprint

Piroxicam
doxorubicin
Transitional Cell Carcinoma
Doxorubicin
carcinoma
Dogs
dogs
Disease-Free Survival
cells
surgery
therapeutics
administered dose
Tumor Burden
prospective studies
disease course
Disease Progression
Prospective Studies
neoplasms
Therapeutics

ASJC Scopus subject areas

  • Small Animals

Cite this

Retrospective evaluation of doxorubicin-piroxicam combination for the treatment of transitional cell carcinoma in dogs. / Robat, C.; Burton, Jenna H; Thamm, D.; Vail, D.

In: Journal of Small Animal Practice, Vol. 54, No. 2, 02.2013, p. 67-74.

Research output: Contribution to journalArticle

@article{9856840d6cb74d14b9066ab7d071969e,
title = "Retrospective evaluation of doxorubicin-piroxicam combination for the treatment of transitional cell carcinoma in dogs",
abstract = "Objectives: To determine whether doxorubicin-piroxicam combination is safe and has activity against transitional cell carcinoma in dogs. Methods: Data was collected retrospectively from 34 dogs from two institutions over a 6-year period. Signalment, clinical presentation, treatment specifics, adverse events, response, progression-free survival and overall survival time were evaluated. Results: Dogs received doxorubicin every 3 weeks and daily piroxicam; 17 dogs (50{\%}) had surgery. Clinical presentations were those typically reported for transitional cell carcinoma. Mean number of doses administered was 3·5. Of the 23 dogs with measurable disease, 14 (60·5{\%}) had stable disease, 7 (30·5{\%}) had progressive disease and 2 (9{\%}) a partial response. Adverse events were generally manageable, and gastrointestinal in origin; one dog died of treatment-related complications. Overall median progression-free survival and overall survival were 103 and 168 days, respectively. Cytoreductive surgery did not result in prolongation of progression-free survival, but significantly prolonged overall survival. All dogs but one died as a result of disease progression. Clinical Significance: Doxorubicin-piroxicam combination therapy is well-tolerated in dogs with transitional cell carcinoma although progression-free survival, overall survival and biological response rates appear modest. Combination with surgery appears to offer a survival advantage; however, this may reflect tumour location and volume. Prospective studies are necessary to compare activity of combination doxorubicin-piroxicam to currently applied therapies.",
author = "C. Robat and Burton, {Jenna H} and D. Thamm and D. Vail",
year = "2013",
month = "2",
doi = "10.1111/jsap.12009",
language = "English (US)",
volume = "54",
pages = "67--74",
journal = "Journal of Small Animal Practice",
issn = "0022-4510",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Retrospective evaluation of doxorubicin-piroxicam combination for the treatment of transitional cell carcinoma in dogs

AU - Robat, C.

AU - Burton, Jenna H

AU - Thamm, D.

AU - Vail, D.

PY - 2013/2

Y1 - 2013/2

N2 - Objectives: To determine whether doxorubicin-piroxicam combination is safe and has activity against transitional cell carcinoma in dogs. Methods: Data was collected retrospectively from 34 dogs from two institutions over a 6-year period. Signalment, clinical presentation, treatment specifics, adverse events, response, progression-free survival and overall survival time were evaluated. Results: Dogs received doxorubicin every 3 weeks and daily piroxicam; 17 dogs (50%) had surgery. Clinical presentations were those typically reported for transitional cell carcinoma. Mean number of doses administered was 3·5. Of the 23 dogs with measurable disease, 14 (60·5%) had stable disease, 7 (30·5%) had progressive disease and 2 (9%) a partial response. Adverse events were generally manageable, and gastrointestinal in origin; one dog died of treatment-related complications. Overall median progression-free survival and overall survival were 103 and 168 days, respectively. Cytoreductive surgery did not result in prolongation of progression-free survival, but significantly prolonged overall survival. All dogs but one died as a result of disease progression. Clinical Significance: Doxorubicin-piroxicam combination therapy is well-tolerated in dogs with transitional cell carcinoma although progression-free survival, overall survival and biological response rates appear modest. Combination with surgery appears to offer a survival advantage; however, this may reflect tumour location and volume. Prospective studies are necessary to compare activity of combination doxorubicin-piroxicam to currently applied therapies.

AB - Objectives: To determine whether doxorubicin-piroxicam combination is safe and has activity against transitional cell carcinoma in dogs. Methods: Data was collected retrospectively from 34 dogs from two institutions over a 6-year period. Signalment, clinical presentation, treatment specifics, adverse events, response, progression-free survival and overall survival time were evaluated. Results: Dogs received doxorubicin every 3 weeks and daily piroxicam; 17 dogs (50%) had surgery. Clinical presentations were those typically reported for transitional cell carcinoma. Mean number of doses administered was 3·5. Of the 23 dogs with measurable disease, 14 (60·5%) had stable disease, 7 (30·5%) had progressive disease and 2 (9%) a partial response. Adverse events were generally manageable, and gastrointestinal in origin; one dog died of treatment-related complications. Overall median progression-free survival and overall survival were 103 and 168 days, respectively. Cytoreductive surgery did not result in prolongation of progression-free survival, but significantly prolonged overall survival. All dogs but one died as a result of disease progression. Clinical Significance: Doxorubicin-piroxicam combination therapy is well-tolerated in dogs with transitional cell carcinoma although progression-free survival, overall survival and biological response rates appear modest. Combination with surgery appears to offer a survival advantage; however, this may reflect tumour location and volume. Prospective studies are necessary to compare activity of combination doxorubicin-piroxicam to currently applied therapies.

UR - http://www.scopus.com/inward/record.url?scp=84873126381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873126381&partnerID=8YFLogxK

U2 - 10.1111/jsap.12009

DO - 10.1111/jsap.12009

M3 - Article

C2 - 23286739

AN - SCOPUS:84873126381

VL - 54

SP - 67

EP - 74

JO - Journal of Small Animal Practice

JF - Journal of Small Animal Practice

SN - 0022-4510

IS - 2

ER -